NGM · Ngm Biopharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $582.0K | $1.42M | $2.25M | - | $7.91M | $8.29M | $20.95M | - | $18.57M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $22.94M | $32.35M | $40.86M | - | $46.11M | $45.43M | $42.81M | - | $38.71M |
| SG&A | - | $8.67M | $9.65M | $11.58M | - | $10.11M | $9.93M | $10.72M | - | $8.87M |
| Total Operating Expenses | - | $31.61M | $42.00M | $52.44M | - | $56.22M | $55.36M | $53.53M | - | $47.58M |
| D&A | - | $500.0K | $600.0K | $609.0K | - | $600.0K | $1.40M | $1.43M | - | $1.50M |
| Operating Income | - | ($31.03M) | ($40.58M) | ($50.19M) | - | ($48.30M) | ($47.07M) | ($32.58M) | - | ($29.01M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($28.80M) | ($38.26M) | ($47.65M) | - | ($47.26M) | ($46.52M) | ($32.45M) | - | ($28.86M) |
| EPS - Basic | - | ($0.35) | ($0.46) | ($0.58) | - | ($0.59) | ($0.59) | ($0.36) | - | ($0.43) |
| EPS - Diluted | - | ($0.35) | ($0.46) | ($0.58) | - | ($0.59) | ($0.59) | ($0.42) | - | ($0.37) |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55.82M | $51.48M | $53.27M | $67.55M | $73.46M | $101.45M | $63.38M | $109.87M | $151.79M | $145.83M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.98M | $4.69M | $5.86M | $13.29M | $8.45M | $3.56M | $6.87M | $4.82M | $5.25M | $7.63M |
| Current Assets | $156.44M | $177.04M | $204.40M | $242.53M | $288.86M | $315.70M | $318.84M | $337.62M | $379.28M | $395.88M |
| Total Assets | $168.87M | $192.15M | $220.54M | $258.84M | $307.40M | $335.87M | $337.37M | $359.77M | $402.39M | $415.86M |
| Current Liabilities | $20.08M | $22.34M | $28.42M | $37.90M | $47.84M | $48.60M | $42.54M | $44.56M | $61.35M | $57.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $20.23M | $22.34M | $28.42M | $37.90M | $47.84M | $49.98M | $45.29M | $48.64M | $66.74M | $61.82M |
| Stockholders' Equity | $148.64M | $169.81M | $192.12M | $220.93M | $259.56M | $285.89M | $292.08M | $311.14M | $335.65M | $354.04M |
| Retained Earnings | ($724.01M) | ($696.34M) | ($667.54M) | ($629.28M) | ($581.63M) | ($545.20M) | ($497.94M) | ($451.42M) | ($418.97M) | ($391.73M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($41.83M) | - | - | - | ($35.74M) | - | - |
| Investing Cash Flow | - | - | - | $35.64M | - | - | - | ($6.85M) | - | - |
| Financing Cash Flow | - | - | - | $279.0K | - | - | - | $668.0K | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -5331.8% | -2851.4% | -2233.8% | - | -610.6% | -567.6% | -155.5% | - | -156.2% |
| EBITDA margin | - | -5245.9% | -2809.2% | -2206.7% | - | -603.0% | -550.7% | -148.7% | - | -148.1% |
| Net margin | - | -4947.9% | -2688.8% | -2120.5% | - | -597.4% | -560.9% | -154.9% | - | -155.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | 3941.9% | 2273.4% | 1818.3% | - | 582.8% | 547.8% | 204.3% | - | 208.4% |
| SG&A / Revenue | - | 1489.9% | 677.9% | 515.5% | - | 127.8% | 119.7% | 51.2% | - | 47.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -15.0% | -17.3% | -18.4% | - | -14.1% | -13.8% | -9.0% | - | -6.9% |
| Return on equity | - | -17.0% | -19.9% | -21.6% | - | -16.5% | -15.9% | -10.4% | - | -8.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.79 | 7.92 | 7.19 | 6.40 | 6.04 | 6.50 | 7.50 | 7.58 | 6.18 | 6.86 |
| Quick ratio | 7.79 | 7.92 | 7.19 | 6.40 | 6.04 | 6.50 | 7.50 | 7.58 | 6.18 | 6.86 |
| Cash ratio | 2.78 | 2.30 | 1.87 | 1.78 | 1.54 | 2.09 | 1.49 | 2.47 | 2.47 | 2.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.13 | 1.15 | 1.17 | 1.18 | 1.17 | 1.16 | 1.16 | 1.20 | 1.17 |
| Liabilities / Assets | 0.12 | 0.12 | 0.13 | 0.15 | 0.16 | 0.15 | 0.13 | 0.14 | 0.17 | 0.15 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.01 | 0.01 | - | 0.02 | 0.02 | 0.06 | - | 0.04 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -92.6% | -82.8% | -89.3% | - | -57.4% | -50.6% | -2.9% | - | -20.9% |
| Revenue CAGR (3y) | - | -70.8% | -58.4% | -54.8% | - | -27.6% | -31.1% | 4.0% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 35.8% | 13.8% | -54.1% | - | -66.5% | -28.5% | -17.0% | - | 3.2% |
| Net income growth (YoY) | - | 39.1% | 17.8% | -46.8% | - | -63.7% | -26.8% | -17.8% | - | 3.0% |
| EPS growth (YoY) | - | 40.7% | 22.0% | -38.1% | - | -59.5% | -22.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -42.7% | -40.6% | -34.2% | -29.0% | -22.7% | -19.2% | -21.7% | -22.1% | 19.9% | 27.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$4.90M totalLicense$4.90M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NGM BIOPHARMACEUTICALS INC against the 5 most active filers in the same SIC group.